Bioven is under clinical development by Biopharma Plasma and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia. According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) Pneumonia have an 8% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Bioven’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bioven overview
Bioven is under development for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 pneumonia caused by the severe acute coronavirus 2 (SARS-COV2) and chronic primary immune thrombocytopenia. The drug candidate comprises of immunoglobulin-G donated from the plasma cells of patients. It is administered through intravenous route.
Biopharma Plasma overview
Biopharma Plasma is a biopharma immunobiological pharmaceutical company that develops and produces human plasma-derived medicines for the treatment of oncological diseases. Biopharma Plasma is headquartered in Kyiv, Ukraine.
For a complete picture of Bioven’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
